The global atopic dermatitis market size was valued at USD 10.33 Billion in 2022 and is likely to reach USD 22.70 Billion by 2031, expanding at a CAGR of 10.32% during the forecast period, 2023–2031. The market growth is attributed to the increasing number of eczema dermatitis cases across the world.
Atopic dermatitis is a chronic skin disease characterized by redness, itchy, and inflamed skin. It is a common disease, particularly in children, and is often associated with asthma or allergies. It causes the skin to become itchy and it leads to further swelling, redness, crusting, cracking, and others.
Environmental triggers can also play a role in triggering or exacerbating atopic dermatitis. These triggers may include irritation such as certain soaps, detergents, fabrics, or chemicals, as well as allergens like dust mites, pet dander, pollen, or certain foods. Stress dry skin, changes in temperature or humidity, and infections can also contribute to flare-ups.
According to the National Institute of Health (NIH), atopic dermatitis affects around 10% to 30% of children and 10% of adults in developed countries. The most common type of atopic dermatitis around 60% of cases starts by age 1, these include diaper rash, eczema, cradle crap, and contact dermatitis, of which around 60% of cases resolve by the age of 12.
The symptoms of atopic dermatitis can vary in intensity and may come and go. Common signs include intense itching, red, or brownish-gray patches of skin, small raised bumps that may ooze or crust over when scratched, thickened or leathery skin, and dry, sensitive skin. The condition often affects areas such as the face, hands, feet, inner elbows, behind the knees, and the neck.
As of now, there is no cure for atopic dermatitis, however, there are various atopic dermatitis treatment options available to manage the symptoms and reduce flare-ups. These may include topical corticosteroids or other anti-inflammatory creams, moisturizers to keep the skin hydrated, antihistamines to alleviate itching, and in severe cases, oral medications, or immunosuppressants.
There are several types of atopic dermatitis or eczema dermatitis including infantile eczema, contact dermatitis, dyshidrotic eczema, stasis dermatitis, and neurodermatitis. Avoiding triggers and adopting a regular skincare routine can help manage the condition effectively.
The market report finds that the COVID-19 pandemic negatively impacted the atopic dermatitis market, due to the strict regulations imposed by the governments. Patients have stopped their biological therapy and other existing treatments with their physicians during the pandemic. During the pandemic, the preference for digital health solutions such as telemedicine and telehealth grew significantly.
Atopic Dermatitis Market Dynamics
Major Drivers
According to the World Health Organization (WHO), the prevalence of skin disorders is increasing which is expected to boost the market. The atopic dermatitis condition is caused after the skin comes in contact with certain chemicals that are used in personal care products and extremely dry winters are the most common causes that prompt the atopic dermatitis market growth.
Changes in climatic conditions are further expected to boost the atopic dermatitis market growth. Some people with atopic dermatitis have an allergy to certain plant pollens that trigger a flare of atopic dermatitis symptoms. Plants produce more pollen in warmer temperatures. Such climatic changes can cause eczema indirectly to individuals on a windy day as the pollen comes onto the skin.
Increasing skin-related diseases is expected to boost the atopic dermatitis market growth. Atopic dermatitis is caused by skin colonization or infection by bacteria such as Staphylococcus aureus. Bacterial infections are characterized by redness and the formation of yellow crusts. Around 60 to 90% of people are likely to have staph bacteria on their skin.
- According to the International Eczema Council (IEC), around 223 million people are living with atopic dermatitis in 2022, of which around 43 million are aged 1 to 4 years. This illustrates the strikingly high prevalence of atopic dermatitis in young children.
Existing Restraints
The high cost of atopic dermatitis treatment and poor reimbursement policies across the world are expected to hamper the market. The large and growing prevalence of atopic dermatitis is increasing the burden on the United States economy. The disease is expected to cost around USD 5 billion each year, the costs include direct and indirect costs. Indirect costs include career modification, lost productivity at work, at school, and reduced quality of life. Direct costs include hospitalizations, prescription medicines, transportation, and visits to healthcare providers.
Emerging Opportunities
Increasing government support for research and development (R&D) is expected to create lucrative opportunities for the atopic market during the forecast period. Several governments are taking initiatives to develop and bring awareness among people about the disease, as they can improve atopic dermatitis treatment options, make treatments more accessible, reduce racial disparities, and improve quality of life. The R&D activities undertaken by the market players are boosting the development of new treatments and drugs thus, creating new potential for market growth.
- For instance, On January 14, 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) approved RINVOQ for the treatment of atopic dermatitis to adults and 12-year-old children and older whose disease did not respond to previous treatment. FDA-approved 2-dose strength (15mg and 30mg). RINVOQ 15 mg once daily can be initiated in adults and children and older weighing at least 40kg.
Scope of Atopic Dermatitis Market Report
The market report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Atopic Dermatitis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Drug Type (PDE4 Inhibitors, CNI Immunosuppressants, Corticosteroids, Skin Barrier Emollients, Antibiotics, Biologics, Calcineurin Inhibitors, and Others), Route of Administration (Topical, Injectable, and Oral), and End-user (Retail Pharmacies, Hospital Pharmacies, Research Centers, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Astellas Pharma Inc.; Sanofi; Regeneron Pharmaceuticals Inc.; Dermala Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Pfizer Inc.; GALDERMA; AstraZeneca; DuPont; Teva Pharmaceutical Industries Ltd.; and AbbVie Inc.
|
Atopic Dermatitis Market Segment Insights
Drug Type Segment Analysis
Based on drug type, the global atopic dermatitis market is segregated into PDE4 inhibitors, CNI immunosuppressants, corticosteroids, skin barrier emollients, antibiotics, biologics, calcineurin inhibitors, and others. The corticosteroids segment is projected to register a considerable CAGR during the forecast period. The corticosteroid drug is used to reduce asthma, rheumatoid arthritis, allergies, and others. Corticosteroids are a medicine that relieves inflammation in the body.
The PDE4 inhibitor segment is estimated to grow at a significant rate during the forecast period, due to the increasing demand for PDE4 inhibitors to make skin ointments for curing skin-related diseases, especially Atopic Dermatitis (AD). The demand for PDE4 inhibitors is increasing as it helps in blocking the breakdown of cyclic adenosine monophosphate which results in a decrease in airway inflammation.
In 2016, The FDA approved Pfizer’s Eucrisa (crisaborole ointment, 2%), a PDE4 inhibitor for treating mild-to-moderate AD. With the continuous R&D in the use of PDE4 for ointments, In March 2020, Eucrisa was approved by the FDA for children of 3 years of age. Furthermore, in January 2021, Arcutis Biotherapeutics announced a phase 3 trial of another important PDE4 roflumilast inhibitor.
Route of Administration Segment Analysis
On the basis of route of administration, the market is segmented into topical, injectable, and oral. The topical segment is expected to register a robust growth rate during the forecast period. Topical atopic dermatitis treatments are medications that are applied to the skin to reduce inflammation and manage symptoms. Topical atopic dermatitis medications are sold as gels, lotions, creams, and foams. They are applied directly to the skin.
The oral segment is projected to hold a key market share in the coming years. Several healthcare industries provide oral pills to control the symptoms. Antihistamines, antibiotics, and many anti-inflammatory medicines are used as oral atopic dermatitis drugs for eczema. Oral atopic medication is also used in home-based therapies.
End-user Segment Analysis
Based on end-user, the atopic dermatitis market is segmented into retail pharmacies, hospital pharmacies, research centers, and others. The hospital pharmacies segment is anticipated to account for a major market share in the coming years, owing to the increasing expansion of clinics and hospitals all over the world.
The demand for atopic dermatitis treatment is increasing, due to the growing number of patients in hospitals. The hospital pharmacies provide ease of buying and convenience to patients who prefer hospitals for AD treatment.
Regional Analysis
In terms of region, the global atopic dermatitis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the global market during the projection period. Rising prevalence of Atopic dermatitis disease in the region is expected to drive the market in the coming years. In North America, especially in the U.S., Atopic dermatitis is a common type of eczema, which impacts more than 9.6 million children and about 16.5 million adults.
As per the Journal of the American Medical Association (JAMA), during early childhood, 31.6 million people (10.1%) suffered from some form of eczema in the U.S. Nearly, 9.6 million children under the age of 18 have AD, among which one-third have moderate to severe disease. With the rapid increase in the number of AD-related patients, the demand for easy-to-apply medications is growing for better treatment and diagnosis is driving the market in the region.
The market in Europe is anticipated to expand at a rapid pace in the coming years, due to strong government assistance in extensive R&D activities coupled with growing funds for the healthcare sector and increasing prevalence of atopic dermatitis.
- According to the National Institutes of Health (NIH), in Europe around 4.4% of adults and up to 18.6% of children have atopic dermatitis, with 20% of all cases accounting for moderate-to-severe forms.
Segments
The global atopic dermatitis market has been segmented on the basis of
Drug Type
- PDE4 Inhibitors
- CNI Immunosuppressants
- Corticosteroids
- Skin Barrier Emollients
- Antibiotics
- Biologics
- Calcineurin Inhibitors
- Others
Route of Administration
End-User
- Retail Pharmacies
- Hospital Pharmacies
- Research Centers
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Astellas Pharma Inc.
- Sanofi
- Regeneron Pharmaceuticals Inc.
- Dermala Inc.
- Novartis Pharmaceuticals Corporation
- Bristol-Myers Squibb Company
- Pfizer Inc.
- GALDERMA
- AstraZeneca
- DuPont
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
Competitive Landscape
Key players competing in the global atopic dermatitis market are Astellas Pharma Inc.; Sanofi; Regeneron Pharmaceuticals Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Pfizer Inc.; GALDERMA; AstraZeneca; DuPont; Teva Pharmaceutical Industries Ltd.; and AbbVie Inc.
These major companies adopt various business development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production capacity expansion to expand their consumer base and enhance their market share. The market report provides in-depth insights into growth strategies and development initiatives implemented by the key players in the market.
-
In February 2023, Pfizer Inc. declared the approval of its supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib) by the (Food and Drug Administration) FDA. CIBINQO was previously approved for treating individuals of around 18 years. It is prepared to treat teenagers (12 to 18 years) with refractory moderate-to-severe atopic dermatitis.
-
In February 2023, Dermavant Sciences made a declaration of the completion of 3 clinical trials of VTAMA (tapinarof) cream 1% for treating children around two years old and grownups with atopic dermatitis.
-
In January 2023, Sanofi declared the approval of Dupixent (dupilumab) by the committee for medicinal products for human use (CHMP) of the European Medicines Agency. It is presently used for wider EU authorization for the treatment of severe atopic dermatitis in children around six months to 5 years, who are candidates for systemic therapy.
- In April 2023, DuPont introduced new low-cyclosiloxane silicone elastomer blends and silicone resin blends for consumers. Some skin products cause skin irritation, rashes, or inflammation, such conditions are expected to control with the help of these blends. These blends protect the well-being and support the shared commitment of DuPont.
-
In June 2022, Dermala Inc. announced the issuance of the patient’s compositions and methods for treating eczema. The Dermala is a science-based consumer dermatology company developing novel, microbiome-based solutions for chronic skin conditions.
Request For Customization
Enquiry Before Buying
Speak With Analyst
